PEPTIDE VACCINATION AGAINST CANCER TESTIS ANTIGENS IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA: AN ONGOING PHASE I STUDY

被引：0
|
作者：
Holmberg, S. [1 ]
Gang, A. Ortved [1 ]
Svane, I. M. [2 ]
Dufva, I. Hogh [1 ]
Hadrup, S. Reker [3 ]
机构：
[1] Herlev Hosp, Dept Hematol, Herlev, Denmark
[2] Herlev Hosp, Ctr Canc Immune Therapy, Herlev, Denmark
[3] Tech Univ Denmark, Sect Vaccinol & Immunol, Copenhagen, Denmark
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1915
引用
收藏
页码：771 / 772
页数：2
相关论文
共 50 条
  • [1] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [2] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [3] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Levis, Mark
    Guerra, Veronica
    Borthakur, Gautam
    Alvarado, Yesid
    DiNardo, Courtney D.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Daver, Naval
    Konopleva, Marina
    Pemmaraju, Naveen
    Ferrajol, Alessandra
    Andreeff, Michael
    Jain, Nitin
    Estrov, Zeev
    Jabbour, Elias J.
    Wierda, William G.
    Pierce, Sherry
    Pinsoy, Maria Rhona
    Xiao, Lianchun
    Ravandi, Farhad
    Cortes, Jorge E.
    HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
  • [4] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
    Platzbecker, Uwe
    Chromik, Joerg
    Kroenke, Jan
    Handa, Hiroshi
    Strickland, Stephen
    Miyazaki, Yasushi
    Wermke, Martin
    Sakamoto, Wataru
    Tachibana, Yoshifumi
    Taube, Tillmann
    Germing, Ulrich
    BMC CANCER, 2022, 22 (01)
  • [5] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
    Uwe Platzbecker
    Joerg Chromik
    Jan Krönke
    Hiroshi Handa
    Stephen Strickland
    Yasushi Miyazaki
    Martin Wermke
    Wataru Sakamoto
    Yoshifumi Tachibana
    Tillmann Taube
    Ulrich Germing
    BMC Cancer, 22
  • [6] Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    OdchimarReissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Demakos, Erin P.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Woodman, Richard C.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    LEUKEMIA RESEARCH, 2020, 94
  • [7] A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium
    Silverman, Lewis R.
    Verma, Amit
    Odchimar-Reissig, Rosalie
    LeBlanc, Amanda
    Najfeld, Vesna
    Gabrilove, Janice
    Isola, Luis
    Espinoza-Delgado, Igor
    Zwiebel, James
    BLOOD, 2008, 112 (11) : 1252 - 1252
  • [8] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Cogle, Christopher
    Ward, Renee
    Shi, Tao
    MacBeth, Kyle J.
    Laille, Eric
    Giordano, Heidi
    Sakoian, Sarah
    Jabbour, Elias
    Kantarjian, Hagop
    Skikne, Barry
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
  • [9] Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium
    Silverman, L.
    Verma, A.
    Odchimar-Reissig, R.
    LeBlane, A.
    Najfeld, V.
    Gabrilove, J.
    Isola, L.
    Espinoza-Delgado, I.
    Zwiebel, J.
    LEUKEMIA RESEARCH, 2009, 33 : S135 - S136
  • [10] Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial
    Holmberg-Thyden, Staffan
    Dufva, Inge Hogh
    Gang, Anne Ortved
    Breinholt, Marie Fredslund
    Schejbel, Lone
    Andersen, Mette Klarskov
    Kadivar, Mohammad
    Svane, Inge Marie
    Gronbaek, Kirsten
    Hadrup, Sine Reker
    El Fassi, Daniel
    BLOOD, 2020, 136
12345